(Q45601177)

English

Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation

scientific article published in July 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation (English)

1 reference

Europe PubMed Central

14 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

El Saleeby CM

1

1 reference

Europe PubMed Central

14 December 2017

Suzich J

2

1 reference

Europe PubMed Central

14 December 2017

Conley ME

3

1 reference

Europe PubMed Central

14 December 2017

DeVincenzo JP

4

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

1 July 2004

1 reference

Europe PubMed Central

14 December 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

14 December 2017

39

1 reference

Europe PubMed Central

14 December 2017

e17-20

1 reference

Europe PubMed Central

14 December 2017

2

1 reference

Europe PubMed Central

14 December 2017

Respiratory virus infections in pediatric hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Community respiratory virus infections in immunocompromised patients with cancer

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat.

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

1 reference

https://api.crossref.org/works/10.1086%2F421779

21 January 2018

Identifiers

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45601177&oldid=2115642982"